嵌合型MUC1-HER2疫苗对小鼠乳腺癌的免疫原性。

Immunogenicity of chimeric MUC1-HER2 vaccine against breast cancer in mice.

作者信息

Gheybi Elaheh, Salmanian Ali Hatef, Fooladi Abbas Ali Imani, Salimian Jafar, Hosseini Hamideh Mahmoodzadeh, Halabian Raheleh, Amani Jafar

机构信息

Applied Biotechnology Research Center, System Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.

Department of Chemistry, Faculty of Science, Ferdowsi University of Mashhad, Mashhad, Iran.

出版信息

Iran J Basic Med Sci. 2018 Jan;21(1):26-32. doi: 10.22038/IJBMS.2017.25686.6335.

OBJECTIVES

Breast cancer is one of the most common cancers in the world and is on the increase. MUC1 and HER2 as tumor-associated antigens (TAAs) are abnormally expressed to some extent in 75-80% of breast cancers. In our present research, a novel chimeric MUC1-HER2 (HM) protein was designed and used to study whether an immune response can be generated against these TAAs. In vitro analysis of the HER2-MUC1 construct confirmed the co-expression of MUC1 and HER2.

MATERIALS AND METHODS

BALB/c mice were immunized with this novel chimeric protein. The humoral immune response was assessed by enzyme-linked immunosorbent assay (ELISA). Then, BALB/c mice were injected subcutaneously 2×105 4T1-MUC1-HER2 tumor cells. Subsequently, tumor size and tumor necrosis measurements, MTT, cytokines assay and survival test were performed.

RESULTS

The results implied a critical role of HER2 and MUC1 antibodies in vaccination against breast cancer. This engineered protein can be a good vaccine to stop breast cancer.

CONCLUSION

The results implied a critical role of HER2 and MUC1 antibodies in vaccination against breast cancer. This engineered protein can be a good vaccine to stop breast cancer.

目的

乳腺癌是世界上最常见的癌症之一，且发病率呈上升趋势。黏蛋白1（MUC1）和人表皮生长因子受体2（HER2）作为肿瘤相关抗原（TAAs），在75% - 80%的乳腺癌中存在一定程度的异常表达。在我们目前的研究中，设计了一种新型嵌合MUC1 - HER2（HM）蛋白，并用于研究是否能针对这些TAAs产生免疫反应。对HER2 - MUC1构建体的体外分析证实了MUC1和HER2的共表达。